A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3507-3516

  Middleton, Gary ^a   Brown, Sarah ^b   Lowe, Catherine ^b   Maughan, Timothy ^c   Gwyther, Stephen ^d   Oliver, Alfred ^e   Richman, Susan ^b   Blake, Denise ^f   Napp, Vicky ^b   Marshall, Helen ^b   Wadsley, Jonathan ^g   Maisey, Nick ^h   Chau, Ian ⁱ   Hill, Mark ^j   Gollins, Simon ^k   Myint, Sun ^l   Slater, Sarah ^m   Wagstaff, John ⁿ   Bridgewater, John ^o   Seymour, Matthew ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d EAST SURREY HOSPITAL   (United Kingdom)

^e NCRN Consumer Liaison Group   (United Kingdom)

^f ROYAL VICTORIA INFIRMARY   (United Kingdom)

^g WESTON PARK HOSPITAL   (United Kingdom)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j Kent Oncology Centre   (United Kingdom)

^k GLAN CLWYD HOSPITAL   (United Kingdom)

^l CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^m ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

ⁿ SINGLETON HOSPITAL   (United Kingdom)

^o UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

Colorectal; Phase III; PICCOLO

Indexed keywords

ANTIDIARRHEAL AGENT; CYCLOSPORIN A; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB;

ADOLESCENT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VOMITING; WILD TYPE;

COLORECTAL; PHASE III; PICCOLO;

ADMINISTRATION, ORAL; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYCLOSPORINE; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ODDS RATIO; P-GLYCOPROTEIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885190578     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.017     Document Type: Article

References (23)

1. D. Cunningham, S. Pyrhönen, and R.D. James Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413 1418
2. M.L. Rothenberg, N.J. Meropol, and E.A. Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 2001 3801 3807
3. â̂-28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 17 2007 1290 1295
4. J.G. Slatter, L.J. Schaaf, and J.P. Sams Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients Drug Metab Dispos 28 2000 423 433
5. R. Khanna, C.L. Morton, M.K. Danks, and P.M. Potter Proficient metabolism of irinotecan by a human intestinal carboxylesterase Cancer Res 60 2000 4725 4728
6. E. Araki, M. Ishikawa, and M. Iigo Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11 Jpn J Cancer Res 84 1993 697 702
7. E. Gupta, T.M. Lestingi, and R. Mick Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res 54 1994 3723 3725
8. M. Bohme, G. Jedlitschky, I. Leier, M. Buchler, and D. Keppler ATP-dependent export pumps and their inhibition by cyclosporins Adv Enzyme Regul 34 1994 371 380
9. B.M.J. Foxwell, A. Mackie, V. Ling, and B. Ryffel Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein Mol Pharmacol 36 1989 543 546
10. B. Le Thai, M. Dumont, and A. Michel Cholestatic effect of cyclosporine in the rat: an inhibition of bile acid secretion Transplantation (Baltimore) 46 1988 510 512
11. E. Gupta, A.R. Safa, and X. Wang Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A Cancer Res 56 1996 1309 1314
12. J.D. Chester, S.P. Joel, and S.L. Cheeseman Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer J Clin Oncol 21 2003 1125 1132
13. M.T. Seymour, S.R. Brown, and G. Middleton Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Lancet Oncol 2013 published online May 29
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors JNCI 92 2000 205 216
15. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 2010 4706 4713
16. J. Bennouna, J. Sastre, and D. Arnold Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 1 2013 29 37
17. E. Van Cutsem, J. Tabernero, and R. Lakomy Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 28 2012 3499 3506
18. T.J. Price, J.E. Hardingham, and C.K. Lee Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer J Clin Oncol 29 19 2011 2675 2682
19. M.H. Raaijmakers, E.P. de Grouw, and B.A. van der Reijden ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia Clin Cancer Res 12 11, Pt. 1 2006 3452 3458
20. M.T. Seymour, T.S. Maughan, and J.A. Ledermann FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152
21. A.F. Sobrero, J. Maurel, and L. Fehrenbacher EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 14 2008 2311 2319
22. S. Fagbemi, L. Iyer, and S. Mani Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine (CSA) Proc Am Soc Clin Oncol 16 1997 219a (abstr 766.5)
23. A.A. Desai, H.L. Kindler, and D. Taber Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer Cancer Chemother Pharmacol 56 2005 421 426